Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed the day trading at $29.23 down -0.95% from the previous closing price of $29.51. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 4.19 million shares were traded. RARE stock price reached its highest trading level at $30.17 during the session, while it also had its lowest trading level at $28.3501.
Ratios:
For a better understanding of RARE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 6.17 whereas as Long-Term Debt/Eq ratio is at 5.70.
On June 06, 2024, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $56 to $67.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.RBC Capital Mkts initiated its Outperform rating on April 22, 2024, with a $77 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2763462656 and an Enterprise Value of 3833900544. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.68 while its Price-to-Book (P/B) ratio in mrq is 19.00. Its current Enterprise Value per Revenue stands at 6.491 whereas that against EBITDA is -8.023.
Stock Price History:
The Beta on a monthly basis for RARE is 0.27, which has changed by -0.35431856 over the last 52 weeks, in comparison to a change of 0.10611236 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $29.03. The 50-Day Moving Average of the stock is -19.68%, while the 200-Day Moving Average is calculated to be -31.32%.
Shares Statistics:
Over the past 3-months, RARE traded about 1.34M shares per day on average, while over the past 10 days, RARE traded about 3200250 shares per day. A total of 93.74M shares are outstanding, with a floating share count of 88.38M. Insiders hold about 6.52% of the company’s shares, while institutions hold 96.30% stake in the company. Shares short for RARE as of 1749772800 were 6081072 with a Short Ratio of 5.08, compared to 1747267200 on 5891832. Therefore, it implies a Short% of Shares Outstanding of 6081072 and a Short% of Float of 6.6599995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
